
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
The American Journal of Managed Care
almost 25 years ago
Effects of an HMO Hospitalist Program on Inpatient Utilizationalmost 25 years ago
Managed Care in the Doctor's Office: Has the Revolution Stalled?almost 25 years ago
A New Measure of the Impact of Managed Care on Healthcare Marketsalmost 25 years ago
Group Practice Strategies to Manage Pharmaceutical Cost in an HMO Networkalmost 25 years ago
Who Will Pay for the Value of Hospitalists?




